Endocrinology Advisor1d
Baqsimi Approved for Severe Hypoglycemia Treatment in Younger Patients
The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.
pharmaphorum6d
CHMP backs Lilly’s Baqsimi as non-injectable for severe low blood sugar
Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.
Monthly Prescribing Reference9d
Baqsimi Approved for Severe Hypoglycemia Treatment in Younger Patients
The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.